Mark A. Schroeder

12.2k total citations · 1 hit paper
213 papers, 7.0k citations indexed

About

Mark A. Schroeder is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Mark A. Schroeder has authored 213 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Hematology, 64 papers in Genetics and 51 papers in Molecular Biology. Recurrent topics in Mark A. Schroeder's work include Hematopoietic Stem Cell Transplantation (50 papers), Glioma Diagnosis and Treatment (36 papers) and Acute Myeloid Leukemia Research (34 papers). Mark A. Schroeder is often cited by papers focused on Hematopoietic Stem Cell Transplantation (50 papers), Glioma Diagnosis and Treatment (36 papers) and Acute Myeloid Leukemia Research (34 papers). Mark A. Schroeder collaborates with scholars based in United States, Canada and Australia. Mark A. Schroeder's co-authors include Jann N. Sarkaria, Brett L. Carlson, John F. DiPersio, Mark S. Wrighton, C. David James, Rolf D. Hubmayr, Nicholas E. Vlahakis, Evanthia Galanis, Caterina Giannini and Gaspar J. Kitange and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Mark A. Schroeder

200 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

2013 489 citations Mark A. Schroeder, C. David James et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark A. Schroeder United States	50	2.7k	1.8k	1.8k	1.4k	1.2k	213	7.0k
Masayoshi Kobune Japan	45	2.9k 1.1×	2.1k 1.1×	1.4k 0.8×	1.4k 1.0×	638 0.6×	173	7.0k
Achille Iolascon Italy	55	3.1k 1.2×	2.7k 1.5×	1.0k 0.6×	2.6k 1.9×	576 0.5×	357	10.3k
Megan S. Lim United States	47	3.0k 1.1×	1.0k 0.6×	2.8k 1.6×	691 0.5×	1.5k 1.3×	230	8.2k
Fei Huang China	35	3.2k 1.2×	977 0.5×	1.7k 0.9×	1.3k 0.9×	452 0.4×	190	6.5k
Bjørn Tore Gjertsen Norway	50	4.8k 1.8×	884 0.5×	2.0k 1.1×	2.4k 1.7×	1.9k 1.6×	291	9.2k
Süleyman Ergün Germany	46	4.1k 1.5×	889 0.5×	2.0k 1.1×	527 0.4×	830 0.7×	222	8.3k
Joseph E. Italiano United States	50	2.9k 1.1×	1.0k 0.6×	1.6k 0.9×	5.1k 3.8×	1.6k 1.4×	133	9.7k
Owen J. T. McCarty United States	48	1.4k 0.5×	2.0k 1.1×	978 0.5×	3.6k 2.6×	1.3k 1.1×	242	7.7k
Andreas E. Kulozik Germany	54	6.4k 2.4×	2.0k 1.1×	879 0.5×	1.5k 1.1×	659 0.6×	230	10.2k
Andréas Bikfalvi France	52	5.0k 1.9×	737 0.4×	1.8k 1.0×	478 0.4×	998 0.9×	182	8.3k

Countries citing papers authored by Mark A. Schroeder

Since Specialization

Citations

This map shows the geographic impact of Mark A. Schroeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Schroeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Schroeder more than expected).

Fields of papers citing papers by Mark A. Schroeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Schroeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Schroeder. The network helps show where Mark A. Schroeder may publish in the future.

Co-authorship network of co-authors of Mark A. Schroeder

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Schroeder. A scholar is included among the top collaborators of Mark A. Schroeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Schroeder. Mark A. Schroeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hobbs, Gabriela, Haesook T. Kim, Mark A. Schroeder, et al.. (2025). Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation. 1 indexed citations

Crees, Zachary, Michael Slade, Mark A. Schroeder, et al.. (2023). Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Blood. 142(Supplement 1). 2217–2217. 1 indexed citations

DeFilipp, Zachariah, Haesook T. Kim, Laura Knight, et al.. (2022). Prolonged Post-Transplant Ruxolitinib Therapy is Associated with Protection from Severe Gvhd after Allogeneic HCT. Transplantation and Cellular Therapy. 28(3). S305–S306. 2 indexed citations

Abboud, Ramzi, Feng Gao, Michael P. Rettig, et al.. (2022). A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(3). S298–S299. 1 indexed citations

Schroeder, Mark A., et al.. (2022). Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. Bone Marrow Transplantation. 57(6). 975–981. 7 indexed citations

Kizilbash, Sani H., Shiv K. Gupta, Karen E. Parrish, et al.. (2021). In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Molecular Cancer Therapeutics. 20(6). 1009–1018. 10 indexed citations

Schroeder, Mark A., H. Jean Khoury, Madan Jagasia, et al.. (2020). A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Advances. 4(8). 1656–1669. 72 indexed citations

Tuscano, Joseph M., Emanual Maverakis, Susan Groshen, et al.. (2019). A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research. 25(23). 7004–7013. 34 indexed citations

Zeidan, Amer M., Hanna A. Knaus, Tara M. Robinson, et al.. (2018). A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research. 24(15). 3519–3527. 74 indexed citations

10.

Savona, Michael R., Daniel A. Pollyea, Wendy Stock, et al.. (2018). Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research. 24(10). 2294–2303. 86 indexed citations

11.

Kizilbash, Sani H., Shiv K. Gupta, Kenneth Tou En Chang, et al.. (2017). Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Molecular Cancer Therapeutics. 16(12). 2735–2746. 60 indexed citations

12.

Mutter, Robert W., Mohamed M. Kahila, Xiaolin Yu, et al.. (2017). The Selective ATR Inhibitor VX-970 Enhances the Therapeutic Effects of Radiation Therapy in Triple Negative Breast Cancer Patient-Derived Xenografts and is a Novel Strategy to Overcome Therapeutic Resistance. International Journal of Radiation Oncology*Biology*Physics. 99(2). E611–E611. 2 indexed citations

13.

Pedrón, Sara, et al.. (2017). Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma. Advanced Healthcare Materials. 6(21). 44 indexed citations

14.

Parrish, Karen E., Ling Cen, J. C. Murray, et al.. (2015). Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics. 14(12). 2735–2743. 66 indexed citations

15.

Pokorny, Jenny L., David Calligaris, Shiv K. Gupta, et al.. (2015). The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma. Clinical Cancer Research. 21(8). 1916–1924. 71 indexed citations

16.

Gupta, Shiv K., Ann C. Mladek, Brett L. Carlson, et al.. (2014). Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts. Clinical Cancer Research. 20(14). 3730–3741. 57 indexed citations

17.

Choi, Jae Won, Mark A. Schroeder, Jann N. Sarkaria, & Richard J. Bram. (2013). Cyclophilin B Supports Myc and Mutant p53-Dependent Survival of Glioblastoma Multiforme Cells. Cancer Research. 74(2). 484–496. 32 indexed citations

18.

Kitange, Gaspar J., Ann C. Mladek, Brett L. Carlson, et al.. (2012). Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts. Clinical Cancer Research. 18(15). 4070–4079. 125 indexed citations

19.

Allen, Cory, Sompong Vongpunsawad, Takafumi Nakamura, et al.. (2006). Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity. Cancer Research. 66(24). 11840–11850. 84 indexed citations

20.

Deschamps, Claude, G. A. Farkas, Kenneth C. Beck, Mark A. Schroeder, & Robert E. Hyatt. (1995). EXPERIMENTAL EMPHYSEMA. Chest Surgery Clinics of North America. 5(4). 691–699. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact